Pluri (NASDAQ:PLUR) Shares Up 0.8% – Should You Buy?

Pluri Inc. (NASDAQ:PLUR)’s share price shot up 0.8% during trading on Thursday . The company traded as high as $2.45 and last traded at $2.38. 11,642 shares traded hands during trading, a decline of 35% from the average session volume of 17,922 shares. The stock had previously closed at $2.36.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Pluri Stock Performance

The firm has a market cap of $25.68 million, a price-to-earnings ratio of -0.53 and a beta of 0.64. The firm has a 50-day moving average price of $3.10 and a two-hundred day moving average price of $3.27.

Pluri (NASDAQ:PLUR) last issued its earnings results on Thursday, May 14th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.11. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.66 million.

Institutional Investors Weigh In On Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC bought a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri as of its most recent filing with the SEC. Hedge funds and other institutional investors own 16.59% of the company’s stock.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.